Quantcast
Study Finds Many Patients Excluded From Clinical Trials Due

Study Finds Many Patients Excluded From Clinical Trials Due To Prior Cancer

UT Southwestern Medical Center Lung cancer clinical trials exclude a substantial proportion of patients due to a history of prior cancer, as shown in an analysis by cancer researchers at UT Southwestern Medical Center. Among more than 50...

Latest Management of cancer Stories

2014-09-29 16:23:53

In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision Resources Group over PR Newswire, we are advised by the company that the headline should read $3.8 billion rather than $3.8 million as originally issued inadvertently. The complete, corrected release follows: The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 billion...

2014-09-29 12:30:45

BOGOTA, Colombia, Sept. 29, 2014 /PRNewswire/ -- Cancer Treatment Institute of Colombia has announced a promising new drug treatment: a carefully formulated, first-of-its-kind combination of salinomycin and 3-bromopyruvate (3-BrPA) that has already proven successful at treating multiple types of cancer. The team of medical researchers behind this novel treatment are optimistic that it could significantly improve outcomes for many patients who have exhausted current therapeutic...

2014-09-26 23:00:20

Treatment designed to reduce pain and inflammation associated with radiation therapy to the lower bowel. Claremont, CA (PRWEB) September 27, 2014 Synedgen announced today the award of a competitive Small Business Innovation Research (SBIR) Phase I contract from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) to demonstrate proof-of-concept activity of Synedgen’s proprietary treatment for radiation proctitis, a condition that causes painful tissue damage to...

2014-09-22 16:29:05

MELBOURNE, Australia, Sept. 22, 2014 /PRNewswire/ -- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company that focuses on the development of new and proprietary treatments for cancer patients, is pleased to announce it has executed an equity purchase agreement (the "EPA") with Southridge Partners II, L.P., an institutional investor, in the amount of $5 million, which will create significant growth capital for Propanc, enabling the...

2014-09-22 04:21:55

LUGANO, Switzerland, September 22, 2014 /PRNewswire/ -- Helsinn Group, a company focused on building quality cancer care, today announces that it is supporting an independent educational satellite symposium on Delivering Chemotherapy With Confidence: New Strategies to Minimize Treatment-Induced Nausea and Vomiting at the 38th European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, in 2014. Helsinn has awarded a grant to prIME oncology, a global...

2014-09-18 12:29:06

Free public open house to feature center tours, food and a chance to meet doctors and staff HAZLETON, Pa., Sept. 18, 2014 /PRNewswire/ -- In partnership with the American Cancer Society, Cancer Treatment Center at Hazleton announces the opening of the ACS Cancer Resource Center for local patients and the community. The Resource Center is now open from 10 a.m. to 4 p.m. on Mondays and Thursdays. http://photos.prnewswire.com/prnvar/20140917/146887 Located inside the Cancer Treatment...

2014-09-18 12:27:44

Several Emerging Therapies Will Expand Treatment Armamentarium for Unresectable Locally Advanced or Metastatic Gastric Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 18, 2014 /PRNewswire/ -- Decision Resources Group finds that the gastric cancer market will grow exponentially from over $1.1 billion in 2013 to nearly $3.8 billion by 2023. Fuelling this growth will be the launch of five targeted therapies for unresectable locally advanced and metastatic...

2014-09-17 16:27:04

SAN DIEGO and PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious disease, cancer and other life-threatening conditions, and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed today that each company will be presenting at the 2014 Exosomes & SingleCell Analysis Summit. http://photos.prnewswire.com/prnvar/20130912/LA78266LOGO On September 18(th),...

2014-09-15 23:07:35

Cianna Medical, Inc: Studies show benefit of targeted radiation for early-stage breast cancer Aliso Viejo, Calif. (PRWEB) September 15, 2014 Cianna Medical, Inc., a women’s health company, today announced five-year results for the first 200 hundred patients treated with the SAVI® breast brachytherapy applicator, including excellent local control, low rates of toxicities and excellent cosmetic results. An additional study of nearly 600 patients with over three years of follow-up...

2014-09-15 16:28:12

Multidisciplinary team composed of six organizations awarded $20,000 for groundbreaking work in mesothelioma and non-small cell lung cancer SYDNEY, Sept. 15, 2014 /PRNewswire/ -- EnGeneIC, Ltd., an emerging biopharmaceutical company focused on revolutionizing the treatment of cancer through the targeted delivery of therapeutic agents directly to cancer cells, announced that, together with the Asbestos Disease Research Institute (ADRI), it has received the 2014 Cancer Institute New...


Word of the Day
humgruffin
  • A terrible or repulsive person.
Regarding the etymology of 'humgruffin,' the OED says (rather unhelpfully) that it's a 'made-up word.' We might guess that 'hum' comes from 'humbug' or possibly 'hum' meaning 'a disagreeable smell,' while 'gruffin' could be a combination of 'gruff' and 'griffin.'